Biotech | March 11, 2022
Emmes acquires Casimir, its fourth major acquisition
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
Casimir further differentiates Emmes’ industry-leading rare disease research capabilities
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies
New results build on previously reported significant recurrence-free survival (rfs) benefit seen in these patients
Expanding the Applied Biosystems portfolio with the latest generation of innovative, mid-throughput genetic analyzers
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline
The 15-year agreement will leverage dedicated commercial fill-finish manufacturing capacity in the US for mRNA vaccines and therapies
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
Subscribe To Our Newsletter & Stay Updated
